Xiubao Ren

机构：Tianjin Medical University Cancer Institute and Hospital, Tianjin Huanhu Hospital, Cixian People's Hospital

发表论文 95 篇 · 总被引 1515 次 · h-index 19

代表论文

• Novel strategies for cancer immunotherapy: counter-immunoediting therapy (2023 · Journal of Hematology & Oncology · 被引 91)
• Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial (2023 · Journal of Thoracic Oncology · 被引 72)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 27)
• BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). (2024 · Journal of Clinical Oncology · 被引 24)
• The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma (2024 · Cancers · 被引 14)
• DC101, an anti-VEGFR2 agent, promotes high-endothelial venule formation and immune infiltration versus SAR131675 and fruquintinib (2023 · Biochemical and Biophysical Research Communications · 被引 12)